Akero Therapeutics Inc . (NASDAQ: AKRO )的首席开发官Yale Catriona最近进行了一系列涉及公司普通股的股票交易。2025年1月27日，Catriona出售的股票总价值约为301万美元。售价范围在每股55.156美元至57.024美元之间，接近公司52周高点58.40美元。该股表现出色，过去一年回报率超过156%，目前市值为38.6亿美元。根据 ...
We recently compiled a list of the 12 Best Booming Stocks to Invest in Now. In this article, we are going to take a look at ...
周二，Citi分析师将Akero Therapeutics (NASDAQ: AKRO )的股票目标价从之前的65美元上调至80美元，同时维持对该股的买入评级。目前该股交易价格为51.71美元，股价势头强劲， InvestingPro ...
Zacks.com on MSN4 天
AKRO Stock Doubles in a Week as Lead Drug Meets Goal in MASH StudyAkero stock soars 106% in a week following initial positive top line 96-week data from a mid-stage MASH study of its lead ...
Akero Therapeutics announced statistically significant results from a Phase 2b trial of efruxifermin this week, a fibroblast ...
What a difference 60 weeks can make. That’s the lesson Akero Therapeutics Inc. shared with the rollout of what executives called “unprecedented” data from the phase IIb Symmetry trial testing ...
clinicaltrialsarena on MSN5 天
Akero’s cirrhosis treatment shows promise in Phase IIb studyAkero Therapeutics has revealed preliminary outcomes from its Phase IIb study of EFX in individuals with compensated ...
In essence, it is expected that Akero Therapeutics is going to release 52-week data from its phase 3 SYNCHRONY Real-World study using EFX to treat F1-F3 MASH patients, in the 1st half of 2026.
Akero Therapeutics, Inc. (NASDAQ:AKRO) released preliminary topline week 96 results from SYMMETRY Phase 2b study evaluating ...
Akero Therapeutics has hit a home run, reporting statistically significant results in two key 96-week metabolic ...
Citi analysts boosted their price target on Akero Therapeutics (NASDAQ:AKRO) shares to $80 from the previous $65, while ...
Data suggests that EFX treatment is effective over a longer ... 27, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈